Acute myeloid leukemia (AML) is the deadliest of all blood cancers, killing around 75-80% of patients within five years. Our laboratory is exploiting cutting-edge high throughput techniques like CRISPR-Cas9 based screening in AML cell lines supplemented with single cell multi-omics in ex-vivo AML patient samples to decipher the intricacies of therapy resistance in AML. We also employ BH3 profiling to scrutinize altered apoptotic dependencies in in vivo and ex vivo model systems. We are focused at delving deeper into the multiverse of AML biology and to probe unexplored therapeutic targets to bring to light novel therapeutic molecules for improvement of disease outcomes.